» Articles » PMID: 15916415

Dopamine D3 Receptor Partial Agonists and Antagonists As Potential Drug Abuse Therapeutic Agents

Overview
Journal J Med Chem
Specialty Chemistry
Date 2005 May 27
PMID 15916415
Citations 94
Authors
Affiliations
Soon will be listed here.
Citing Articles

Selective dopamine D3 receptor partial agonist (±)VK4-40 reduces the reinforcing strength of d-amphetamine but not cocaine in rhesus monkeys responding under a progressive-ratio schedule of reinforcement.

Allen M, Lewis E, Cao J, Newman A, Nader M Drug Alcohol Depend. 2024; 265:112494.

PMID: 39527868 PMC: 11588530. DOI: 10.1016/j.drugalcdep.2024.112494.


Unveiling the Differences in Signaling and Regulatory Mechanisms between Dopamine D and D Receptors and Their Impact on Behavioral Sensitization.

Kim K Int J Mol Sci. 2023; 24(7).

PMID: 37047716 PMC: 10095578. DOI: 10.3390/ijms24076742.


Design and Synthesis of Conformationally Flexible Scaffold as Bitopic Ligands for Potent D-Selective Antagonists.

Kim H, Lee J, Hsieh C, Taylor M, Luedtke R, Mach R Int J Mol Sci. 2023; 24(1).

PMID: 36613875 PMC: 9820167. DOI: 10.3390/ijms24010432.


Approach to the specificity and selectivity between D2 and D3 receptors by mutagenesis and binding experiments part I: Expression and characterization of D2 and D3 receptor mutants.

Legros C, Rojas A, Dupre C, Brasseur C, Riest-Fery I, Muller O Protein Sci. 2022; 31(12):e4459.

PMID: 36177735 PMC: 9667827. DOI: 10.1002/pro.4459.


A highly DR-selective and efficacious partial agonist (S)-ABS01-113 compared to its DR-selective antagonist enantiomer (R)-ABS01-113 as potential treatments for opioid use disorder.

Galaj E, Bi G, Klein B, Hempel B, Shaik A, Gogarnoiu E Neuropsychopharmacology. 2022; 47(13):2309-2318.

PMID: 35879349 PMC: 9309443. DOI: 10.1038/s41386-022-01379-1.